Patent application number | Description | Published |
20080267915 | Hcv Ns3-Ns4a Protease Inhibition - The present invention relates to inhibiting the activity of non-genotype 1 hepatitis C virus (HCV) NS3-NS4A protease activity. More particularly, the invention relates to inhibiting the activity of the protease from HCV genotype-2 or HCV genotype-3. The methods of the invention emply inhibitors that act by interfering with the life cycle of the HCV and are also useful as antiviral agents. The invention further relates to compositions comprising such compounds either for ex vivo use or for administration to a patient suffering from genotype-2 or genotype-3 HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. | 10-30-2008 |
20090191555 | HCV NS3-NS4 Protease Resistance Mutants - The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment. | 07-30-2009 |
20100172866 | Combination Therapy for the Treatment of HCV Infection - The present invention relates to therapeutic combinations comprising a protease inhibitor and a polymerase inhibitor for the treatment of HCV. The present invention also relates to therapeutic combinations comprising VX-950 and a polymerase inhibitor. Also within the scope of the invention are methods using the therapeutic combinations of the present invention for treating HCV infection or alleviating one or more symptoms thereof in a patient. The present invention also provides kits comprising the combinations of the present invention. | 07-08-2010 |
20110059886 | HCV NS3-NS4A Protease Inhibition - The present invention relates to inhibiting the activity of non-genotype 1 hepatitis C virus (HCV) NS3-NS4A protease activity. More particularly, the invention relates to inhibiting the activity of the protease from HCV genotype-2 or HCV genotype-3. The methods of the invention emply inhibitors that act by interfering with the life cycle of the HCV and are also useful as antiviral agents. The invention further relates to compositions comprising such compounds either for ex vivo use or for administration to a patient suffering from genotype-2 or genotype-3 HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. | 03-10-2011 |
20110086006 | HCV NS3-NS4 Protease Resistance Mutants - The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment. | 04-14-2011 |
20110244549 | HEPATITIS C VIRUS VARIANTS - The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient. | 10-06-2011 |
20120129155 | METHODS FOR AMPLIFYING HEPATITIS C VIRUS NUCLEIC ACIDS - A method of amplifying an HCV nucleic acid in an HCV infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR, wherein a first stage PCR employs a first outer primer and a second outer primer, and a second stage PCR employs a first inner primer and a second inner primer. The nucleotide sequence of the first outer primer comprises a nucleotide sequence as set forth in SEQ ID NO: 2; or SEQ ID NO:9, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 9. The nucleotide sequence of the second outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 3 or 4; or a nucleotide sequence as set forth in SEQ ID NO: 10 or 11, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 10 and 11. The nucleotide sequence of the first inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 5; or SEQ ID NO:12, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 12. The nucleotide sequence of the second inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 6 or 7; or a nucleotide sequence as set forth in SEQ ID NO: 13 or 14, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 13 and 14. | 05-24-2012 |
20120171245 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 07-05-2012 |
20120295843 | COMBINATION THERAPY FOR THE TREATMENT OF HCV INFECTION - The present invention relates to therapeutic combinations comprising a protease inhibitor and a polymerase inhibitor for the treatment of HCV. The present invention also relates to therapeutic combinations comprising VX-950 and a polymerase inhibitor. Also within the scope of the invention are methods using the therapeutic combinations of the present invention for treating HCV infection or alleviating one or more symptoms thereof in a patient. The present invention also provides kits comprising the combinations of the present invention. | 11-22-2012 |
20130344476 | HEPATITIS C VIRUS VARIANTS - The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient. | 12-26-2013 |
20140199684 | METHODS FOR AMPLIFYING HEPATITIS C VIRUS NUCLEIC ACIDS - A method of amplifying an HCV nucleic acid in an HCV infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR, wherein a first stage PCR employs a first outer primer and a second outer primer, and a second stage PCR employs a first inner primer and a second inner primer. The nucleotide sequence of the first outer primer comprises a nucleotide sequence as set forth in SEQ ID NO: 2; or SEQ ID NO:9, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 9. The nucleotide sequence of the second outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 3 or 4; or a nucleotide sequence as set forth in SEQ ID NO: 10 or 11, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 10 and 11. The nucleotide sequence of the first inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 5; or SEQ ID NO:12, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 12. The nucleotide sequence of the second inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 6 or 7; or a nucleotide sequence as set forth in SEQ ID NO: 13 or 14, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 13 and 14. | 07-17-2014 |
20140296201 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 10-02-2014 |
Patent application number | Description | Published |
20080259422 | SELECTIVE PHOTOCOAGULATION - A method of scanning a laser beam across a set of cells includes during a first interval, scanning a laser beam across a set of cells; and during a second interval, deflecting the laser beam away from the set of cells. The first interval is selected to cause microcavitation in at least a portion of the cells from the set of cells. | 10-23-2008 |
20080281306 | SELECTIVE PHOTOCOAGULATION - A method of scanning a laser beam across a set of cells includes during a first interval, causing a galvanometric scanner to scan a laser beam across a set of cells; and during a second interval, causing the galvanometric scanner to deflect the laser beam away from the set of cells. The first interval is selected to cause microcavitation in at least a portion of the cells from the set of cells. | 11-13-2008 |
20100049041 | IN VIVO FLOW CYTOMETRY SYSTEM AND METHOD - The present invention provides methods and systems for performing in vivo flow cytometry. In one embodiments, selected circulating cells of interest of a subject are labeled with fluorescent probe molecules. The labeled cells are irradiated in vivo so as to excite the fluorescent probes, and the radiation emitted by the excited probes is detected, preferably confocally. The detected radiation is then analyzed to derive desired information, such as relative cell count, of the cells of interest. | 02-25-2010 |
20100233092 | IN-VIVO MONITORING OF CIRCULATING APOPTOTIC CELLS - The present invention provides methods and systems for performing in vivo flow cytometry. In one embodiments, selected circulating cells of interest of a subject are labeled with fluorescent probe molecules. The labeled cells are irradiated in-vivo so as to excite the fluorescent probes, and the radiation emitted by the excited probes is detected, preferably confocally. The detected radiation is then analyzed to derive desired information, such as relative cell count, of the cells of interest. In some embodiments, the circulating cells comprise apoptotic cells whose detection can allow, e.g., non-invasive monitoring of the efficacy of a cancer treatment, such as an anti-tumor or an anti-angiogenic therapy. | 09-16-2010 |
20110044910 | IN VIVO FLOW CYTOMETRY BASED ON CELLULAR AUTOFLUORESCENCE - The present invention generally provides methods and systems for performing in vivo flow cytometry by using blood vessels as flow chambers through which flowing cells can be monitored in a live subject in vivo without the need for withdrawing a blood sample. In some embodiments, one or more blood vessels are illuminated with radiation so as to cause a multi-photon excitation of an exogenous fluorophore that was previously introduced into the subject to label one or more cell types of interest. In some other embodiments, rather than utilizing an exogenous fluorophore, endogenous (intrinsic) cellular fluorescence can be employed for in vivo flow cytometry. The emission of fluorescence radiation from such fluorophores in response to the excitation can be detected and analyzed to obtain information regarding a cell type of interest. | 02-24-2011 |
20110060232 | RETINAL FLOW CYTOMETRY - The present invention provides methods and devices for performing flow cytometry. In one embodiment, blood circulating through one or more retinal blood vessels of a subject is illuminated in-vivo so as to excite a plurality of fluorescent-labeled cells contained in the blood. The fluorescence radiation emitted by the excited cells is then detected and analyzed to count the cells from which fluorescence is detected. | 03-10-2011 |
20120029490 | DOSE DETERMINATION FOR INDUCING MICROCAVITATION IN RETINAL PIGMENT EPITHELIUM (RPE) - Methods and systems for controlling selective targeting of retinal pigment epithelium (RPE) cells within a treatment region of the RPE. The methods include (a) depositing a selected amount of energy on a test region of the RPE; (b) determining an extent to which microcavitation has occurred in the test region; and (c) on the basis of the determination, either depositing the selected amount of energy on the treatment region, or depositing an increased amount of energy on the test region, and repeating steps (b) and (c). | 02-02-2012 |
20120136258 | Retinal Flow Cytometry - The present invention provides methods and devices for performing flow cytometry. In one embodiment, blood circulating through one or more retinal blood vessels of a subject is illuminated in-vivo so as to excite a plurality of fluorescent-labeled cells contained in the blood. The fluorescence radiation emitted by the excited cells is then detected and analyzed to count the cells from which fluorescence is detected. | 05-31-2012 |
20120296320 | OPTICAL DEVICES AND METHODS FOR SELECTIVE AND CONVENTIONAL PHOTOCOAGULATION OF THE RETINAL PIGMENT EPITHELIUM - The present invention provides devices and methods for applying radiation to the retina of a patient. In one embodiment, an apparatus includes a radiation source for generating a radiation beam suitable for absorption by retinal pigment epithelial cells. One or more optical components are included to direct the beam onto the retina. A scanner is optically coupled to the radiation source to control movement of the beam in two dimensions to allow a scan over the retina. A controller applies control signals to the scanner to adjust beam movement to illuminate a plurality of retinal locations in a temporal sequence according to a predefined pattern. The device can be operated in one mode to effect selective targeting of retinal pigment epithelial cells, or in another mode to effect thermal photocoagulation of the retina. | 11-22-2012 |
20140031647 | IN VIVO FLOW CYTOMETRY BASED ON CELLULAR AUTOFLUORESCENCE - The present invention generally provides methods and systems for performing in vivo flow cytometry by using blood vessels as flow chambers through which flowing cells can be monitored in a live subject in vivo without the need for withdrawing a blood sample. In some embodiments, one or more blood vessels are illuminated with radiation so as to cause a multi-photon excitation of an exogenous fluorophore that was previously introduced into the subject to label one or more cell types of interest. In some other embodiments, rather than utilizing an exogenous fluorophore, endogenous (intrinsic) cellular fluorescence can be employed for in vivo flow cytometry. The emission of fluorescence radiation from such fluorophores in response to the excitation can be detected and analyzed to obtain information regarding a cell type of interest. | 01-30-2014 |
20140350394 | SYSTEMS AND METHODS FOR SENSING, ENUMERATING AND IMAGING RARE CELLS WITH DIFFUSE LIGHT - Diffuse fluorescence flow cytometers and methods of using them include a plurality of excitation sources and a plurality of detectors, all circumferentially arranged about a space for accommodating a limb of a subject. Tomographic reconstructions of cells within the limb are made by varying the intensity and direction of excitation and then analyzing the results. | 11-27-2014 |
Patent application number | Description | Published |
20080255101 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed. | 10-16-2008 |
20090042819 | Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use - The invention describes novel organic nitric oxide donor salts of a antimicrobial compounds, and novel compositions and kits comprising at least one organic nitric oxide donor salt of an antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. In one embodiment the antimicrobial compounds of the invention are aztreonam, ciprofloxacin, doripenam, duramycin and tobramycin. The organic nitric oxide donors that form salts are preferably organic nitrates, organic nitrites, nitrosothiols, thionitrites and heterocyclic nitric oxide donors. The heterocyclic nitric oxide donors are preferably furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines. The methods of the invention are preferably for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis and for treating | 02-12-2009 |
20090215838 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE - The invention describes compositions and kits comprising at least one organic nitric oxide enhancing salt of an angiotensin π antagonist, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The organic nitric oxide enhancing compounds that form salts with the angiotensin II antagonists are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and/or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines. | 08-27-2009 |
20100093671 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders. | 04-15-2010 |
20100093708 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders. | 04-15-2010 |
20100137291 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders. | 06-03-2010 |
20110098253 | Nitrosated Nonsteroidal Antiinflammatory Compounds, Compositions and Methods of Use - The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders comprising administration of novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. | 04-28-2011 |
Patent application number | Description | Published |
20110191271 | IMAGE TAGGING BASED UPON CROSS DOMAIN CONTEXT - A method described herein includes receiving a digital image, wherein the digital image includes a first element that corresponds to a first domain and a second element that corresponds to a second domain. The method also includes automatically assigning a label to the first element in the digital image based at least in part upon a computed probability that the label corresponds to the first element, wherein the probability is computed through utilization of a first model that is configured to infer labels for elements in the first domain and a second model that is configured to infer labels for elements in the second domain. The first model receives data that identifies learned relationships between elements in the first domain and elements in the second domain, and the probability is computed by the first model based at least in part upon the learned relationships. | 08-04-2011 |
20120163707 | MATCHING TEXT TO IMAGES - Text in web pages or other text documents may be classified based on the images or other objects within the webpage. A system for identifying and classifying text related to an object may identify one or more web pages containing the image or similar images, determine topics from the text of the document, and develop a set of training phrases for a classifier. The classifier may be trained and then used to analyze the text in the documents. The training set may include both positive examples and negative examples of text taken from the set of documents. A positive example may include captions or other elements directly associated with the object, while negative examples may include text taken from the documents, but from a large distance from the object. In some cases, the system may iterate on the classification process to refine the results. | 06-28-2012 |
20130204608 | IMAGE ANNOTATIONS ON WEB PAGES - An image in a web page may be annotated after deriving information about an image when the image may be displayed on multiple web pages. The web pages that show the image may be analyzed in light of each other to determine metadata about the image, then various additional content may be added to the image. The additional content may be hyperlinks to other webpages. The additional content may be displayed as annotations on top of the images and in other manners. Many embodiments may perform searching, analysis, and classification of images prior to the web page being served. | 08-08-2013 |
20130315480 | MATCHING TEXT TO IMAGES - Text in web pages or other text documents may be classified based on the images or other objects within the webpage. A system for identifying and classifying text related to an object may identify one or more web pages containing the image or similar images, determine topics from the text of the document, and develop a set of training phrases for a classifier. The classifier may be trained and then used to analyze the text in the documents. The training set may include both positive examples and negative examples of text taken from the set of documents. A positive example may include captions or other elements directly associated with the object, while negative examples may include text taken from the documents, but from a large distance from the object. In some cases, the system may iterate on the classification process to refine the results. | 11-28-2013 |
20140129489 | IMAGE TAGGING BASED UPON CROSS DOMAIN CONTEXT - A method described herein includes receiving a digital image, wherein the digital image includes a first element that corresponds to a first domain and a second element that corresponds to a second domain. The method also includes automatically assigning a label to the first element in the digital image based at least in part upon a computed probability that the label corresponds to the first element, wherein the probability is computed through utilization of a first model that is configured to infer labels for elements in the first domain and a second model that is configured to infer labels for elements in the second domain. The first model receives data that identifies learned relationships between elements in the first domain and elements in the second domain, and the probability is computed by the first model based at least in part upon the learned relationships. | 05-08-2014 |
Patent application number | Description | Published |
20100327925 | CALIBRATING MULTIPLYING-DELAY-LOCKED-LOOPS (MDLLS) - Devices and methods for varying individual periods or cycle times of upconverted clock signals within a corresponding reference clock cycle are disclosed. In some embodiments, these varying cycle times may improve signal synchronization between the upconverted clock and the reference clock. In different embodiments, different types of counters and counting circuits keep track of the number of elapsed upconverted clock cycles in order to determine the specific upconverted clock cycles with longer cycle times. In some embodiments, a signal may be sent to a delay line to change the amount of delay between upconverted clock pulses, thereby increasing or decreasing a specific upconverted clock cycle time or period. In some embodiments the specific upconverted clock cycle(s) changed in each reference clock cycle may vary, which may further improve reconciliation between the upconverted clock cycles and the corresponding reference clock cycle. | 12-30-2010 |
20100327934 | DIGITAL DELAY LINES - Some embodiments provide real-time variable delays in a delay line. In some of these embodiments, the real-time variable delays may be enable without producing clock glitches. In an embodiment, delay cells in a delay line may be coupled together in a chain to form a lattice of inverters providing different paths of signal propagation. Each path may have a different number of inverters; each inverter adding a known processing time associated with the signal inversion process. In some embodiments, an input signal may be propagated in an inverted or non-inverted form to the inputs of multiple inverters in the lattice, including the inputs of inverters through which the input signal does not propagate. A desired delay time may be obtained in an embodiment by selecting a path containing a desired number and configuration of inverters. The path may be selected in an embodiment using switchably enabled inverters. | 12-30-2010 |
20120262315 | SELF-TIMED DIGITAL-TO-ANALOG CONVERTER - A tracking module that tracks the operation of a digital-to-analog converter (DAC). The DAC tracking module may be included on-chip with a DAC, and be formed with similar circuit components as a DAC. The DAC tracking circuit may output a signal indicating that the DAC within a SAR ADC has settled to an approximate value during each bit conversion. A differential solution is also provided. Power may be optimized because optimal conversion speed may be achieved, and a comparator within the DAC may be turned off or placed in a standby mode at the end of bit conversions, and before the next conversion cycle in response to the signal output by the DAC tracking module. | 10-18-2012 |
Patent application number | Description | Published |
20100144730 | PYRIDINONYL PDK1 INHIBITORS - The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same. | 06-10-2010 |
20100160258 | Bicyclic aryl sphingosine 1-phosphate analogs - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 06-24-2010 |
20100160357 | Heterobicyclic sphingosine 1-phosphate analogs - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 06-24-2010 |
20100240617 | BICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 09-23-2010 |
20110152260 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase - The present invention relates to modulators of IRAK kinases of formula (I) and provides compositions comprising such modulators, as well as methods therewith for treating IRAK-mediated or IRAK-associated conditions or diseases. | 06-23-2011 |
20120190649 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 07-26-2012 |
20120208819 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS - The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases. | 08-16-2012 |
20130059821 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the SIP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SIP receptors. | 03-07-2013 |
20140100195 | Heterobicyclic sphingosine 1-phosphate analogs - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 04-10-2014 |
20150018351 | PYRIDINONYL PDK1 INHIBITORS - The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same. | 01-15-2015 |
Patent application number | Description | Published |
20090169958 | Ceramic interconnect for fuel cell stacks - A fuel cell comprises a plurality of sub-cells, each sub-cell including a first electrode in fluid communication with a source of oxygen gas, a second electrode in fluid communication with a source of a fuel gas, and a solid electrolyte between the first electrode and the second electrode. The sub-cells are connected with each other with an interconnect. The interconnect includes a first layer in contact with the first electrode of each cell, and a second layer in contact with the second electrode of each cell. The first layer includes a (La,Mn)Sr-titanate based perovskite represented by the empirical formula of La | 07-02-2009 |
20100167164 | SOFC Cathode and Method for Cofired Cells and Stacks - A solid oxide fuel cell includes an anode layer, an electrolyte layer over a surface of the anode layer, and a cathode layer over a surface of the electrolyte layer. The cathode layer includes a cathode bulk layer, a porous cathode functional layer at an electrolyte, an intermediate cathode layer partitioning the cathode bulk layer and the porous cathode functional layer, the porous intermediate cathode layer having a porosity greater than that of the cathode bulk layer. The solid oxide fuel cells can be combined to form subassemblies that are bonded together to form solid oxide fuel cell assemblies. | 07-01-2010 |
20100167170 | Co-doped YSZ electrolytes for solid oxide fuel cell stacks - A solid oxide fuel cell electrolyte is fabricated by combining an yttria-stabilized zirconia powder with α-Al | 07-01-2010 |
20100183947 | Highly Sinterable Lanthanum Strontium Titanate Interconnects Through Doping - An interconnect material is formed by combining a lanthanum-doped strontium titanate with an aliovalent transition metal to form a precursor composition and sintering the precursor composition to form the interconnect material. The aliovalent transition metal can be an electron-acceptor dopant, such as manganese, cobalt, nickel or iron, or the aliovalent transition metal can be an electron-donor dopant, such as niobium or tungsten. A solid oxide fuel cell, or a strontium titanate varistor, or a strontium titanate capacitor can include the interconnect material that includes a lanthanum-doped strontium titanate that is further doped with an aliovalent transition metal. | 07-22-2010 |
20130093129 | METHOD OF FORMING A SOLID OXIDE FUEL CELL - A method for forming a solid oxide fuel cell (SOFC) article includes forming a SOFC unit cell in a single, free-sintering process, wherein the SOFC unit cell is made of an electrolyte layer, an interconnect layer, a first electrode layer disposed between the electrolyte layer and the interconnect layer. The electrolyte layer of the SOFC unit cell is in compression after forming. | 04-18-2013 |
20130137014 | SOLID OXIDE FUEL CELL INTERCONNECT CELLS - A bonding layer, disposed between an interconnect layer and an electrode layer of a solid oxide fuel cell article, may be formed from a yttria stabilized zirconia (YSZ) powder having a monomodal particle size distribution (PSD) with a d | 05-30-2013 |
20130177831 | SOLID OXIDE FUEL CELL INTERCONNECTS INCLUDING A CERAMIC INTERCONNECT MATERIAL AND PARTIALLY STABILIZED ZIRCONIA - An interconnect of a solid oxide fuel cell article is disclosed. The interconnect is disposed between a first electrode and a second electrode of the solid oxide fuel cell article. The interconnect comprises a first phase including a ceramic interconnect material and a second phase including partially stabilized zirconia. The partially stabilized zirconia may be in a range of between about 0.1 vol % and about 70 vol % of the total volume of the interconnect. | 07-11-2013 |
20140099567 | CERAMIC INTERCONNECT FOR FUEL CELL STACKS - A fuel cell comprises a plurality of sub-cells, each sub-cell including a first electrode in fluid communication with a source of oxygen gas, a second electrode in fluid communication with a source of a fuel gas, and a solid electrolyte between the first electrode and the second electrode. The sub-cells are connected with each other with an interconnect. The interconnect includes a first layer in contact with the first electrode of each cell, and a second layer in contact with the second electrode of each cell. The first layer includes a (La,Mn)Sr-titanate based perovskite represented by the empirical formula of La | 04-10-2014 |
20150079494 | SOLID OXIDE FUEL CELL INTERCONNECT CELLS - A bonding layer, disposed between an interconnect layer and an electrode layer of a solid oxide fuel cell article, may be formed from a yttria stabilized zirconia (YSZ) powder having a monomodal particle size distribution (PSD) with a d | 03-19-2015 |
Patent application number | Description | Published |
20110203632 | PHOTOVOLTAIC DEVICES USING SEMICONDUCTING NANOTUBE LAYERS - Photovoltaic (PV) devices employing layers of semiconducting carbon nanotubes as light absorption elements are disclosed. In one aspect a layer of p-type carbon nanotubes and a layer of n-type carbon nanotubes are used to form a p-n junction PV device. In another aspect a mixed layer of p-type and n-type carbon nanotubes are used to form a bulk hetero-junction PV device. In another aspect a metal such as a low work function metal electrode is formed adjacent to a layer of semiconducting nanotubes to form a Schottky barrier PV device. In another aspect various material deposition techniques well suited to working with nanotube layers are employed to realize a practical metal-insulator-semiconductor (MIS) PV device. In another aspect layers of metallic nanotubes are used to provide flexible electrode elements for PV devices. In another aspect layers of metallic nanotubes are used to provide transparent electrode elements for PV devices. | 08-25-2011 |
20110244121 | METHODS FOR ARRANGING NANOTUBE ELEMENTS WITHIN NANOTUBE FABRICS AND FILMS - A method for arranging nanotube elements within nanotube fabric layers and films is disclosed. A directional force is applied over a nanotube fabric layer to render the fabric layer into an ordered network of nanotube elements. That is, a network of nanotube elements drawn together along their sidewalls and substantially oriented in a uniform direction. In some embodiments this directional force is applied by rolling a cylindrical element over the fabric layer. In other embodiments this directional force is applied by passing a rubbing material over the surface of a nanotube fabric layer. In other embodiments this directional force is applied by running a polishing material over the nanotube fabric layer for a predetermined time. Exemplary rolling, rubbing, and polishing apparatuses are also disclosed. | 10-06-2011 |
20110291315 | METHODS FOR ARRANGING NANOSCOPIC ELEMENTS WITHIN NETWORKS, FABRICS, AND FILMS - A method for arranging nanotube elements within nanotube fabric layers and films is disclosed. A directional force is applied over a nanotube fabric layer to render the fabric layer into an ordered network of nanotube elements. That is, a network of nanotube elements drawn together along their sidewalls and substantially oriented in a uniform direction. In some embodiments this directional force is applied by rolling a cylindrical element over the fabric layer. In other embodiments this directional force is applied by passing a rubbing material over the surface of a nanotube fabric layer. In other embodiments this directional force is applied by running a polishing material over the nanotube fabric layer for a predetermined time. Exemplary rolling, rubbing, and polishing apparatuses are also disclosed. | 12-01-2011 |
20130133718 | Photovoltaic Devices Using Semiconducting Nanotube Layers - Photovoltaic (PV) devices employing layers of semiconducting carbon nanotubes as light absorption elements are disclosed. In one aspect a layer of p-type carbon nanotubes and a layer of n-type carbon nanotubes are used to form a p-n junction PV device. In another aspect a mixed layer of p-type and n-type carbon nanotubes are used to form a bulk hetero-junction PV device. In another aspect a metal such as a low work function metal electrode is formed adjacent to a layer of semiconducting nanotubes to form a Schottky barrier PV device. In another aspect various material deposition techniques well suited to working with nanotube layers are employed to realize a practical metal-insulator-semiconductor (MIS) PV device. In another aspect layers of metallic nanotubes are used to provide flexible electrode elements for PV devices. In another aspect layers of metallic nanotubes are used to provide transparent electrode elements for PV devices. | 05-30-2013 |
Patent application number | Description | Published |
20080260736 | Methods and Compositions to Regulate Iron Metabolism - The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders. | 10-23-2008 |
20090209478 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE HAMP GENE - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition. | 08-20-2009 |
20100204307 | Compositions And Methods For Inhibiting Expression Of The HAMP Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition. | 08-12-2010 |
20110269823 | Compositions And Methods For Inhibiting Expression Of The HAMP Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition. | 11-03-2011 |
20120064076 | METHODS AND COMPOSITION TO REGULATE IRON METABOLISM - The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders. | 03-15-2012 |
20120164140 | HEMOJUVELIN FUSION PROTEINS AND USES THEREOF - The present invention provides a hemojuvelin (HJV) fusion protein (e.g., a human HJV.Fc) protein, polynucleotides and vectors encoding such proteins, and methods for making such proteins. Also provided are methods for treating iron-related disorders which include administration of a HJV fusion protein to a patient in need thereof. | 06-28-2012 |
20120258105 | METHODS AND COMPOSITIONS TO REGULATE IRON METABOLISM - The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders. | 10-11-2012 |
20120321700 | Compositions And Methods For Inhibiting Expression Of The HAMP Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition. | 12-20-2012 |
20130149304 | USE OF MODULATORS OF COMPOUNDS OF TGF-BETA SUPERFAMILY TO REGULATE HEPCIDIN-MEDIATED IRON METABOLISM - The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders. | 06-13-2013 |
20130243849 | Compositions And Methods For Inhibiting Expression Of The HAMP Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition. | 09-19-2013 |
20140086919 | METHODS AND COMPOSITONS FOR REGULATING IRON HOMEOSTASIS BY MODULATION OF BMP-6 - Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of hemochromatosis and anemia of inflammation. | 03-27-2014 |
20140199302 | COMPOSITIONS FOR REGULATING IRON HOMEOSTASIS AND METHODS OF USING SAME - The present disclosure relates to hemojuvelin-IgG Fc domain fusion proteins, variants, derivatives, fragments and peptide mimetics derived therefrom and methods of using these fusion proteins for the regulation of iron homeostasis and the treatment of diseases related to iron homeostasis. | 07-17-2014 |
20140199314 | METHODS AND COMPOSITIONS FOR REGULATING IRON HOMEOSTASIS BY MODULATION OF BMP-6 - Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of anemia and anemia of inflammation. | 07-17-2014 |
20140294936 | Compositions And Methods For Inhibiting Expression Of The HAMP Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition. | 10-02-2014 |
20150072927 | METHODS AND COMPOSITIONS TO REGULATE HEPCIDIN EXPRESSION - The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders. | 03-12-2015 |
Patent application number | Description | Published |
20110161409 | MEDIA MASHUP SYSTEM - A media mashup system functions as a virtualizable endpoint called an Intelligent Multimedia Pod, or IMP, that ensures a reliable and high-quality multimedia user-experience for a variety of mobile user devices such as intelligent phones etc. The media mashup platform uses a web 2.0 media mashup model that offers several key features including Near Real Time (NRT) service continuity, control-proxy for a mobile-friendly web-surfing experience, finely-filtered content aggregation based on meta-data, context sensors and buddy blaster content sharing/recommendation. These features are brought together using a web 2.0 service mashup model that integrates media meta-data together with various context sensors including mobility-related sensors such as location and presence, time-of-day, voice commands, as well as time-shifted playback. | 06-30-2011 |
20110191414 | METHOD AND APPARATUS FOR EFFICIENT HTTP STREAMING - A method and apparatus provide streaming delivery of data such as media data (video, audio) using a non-streaming delivery mechanism such as HTTP along with server-side pacing of the delivery. An initial portion of the media data is preloaded to a client buffer in a bursting manner to minimize latency. The method may include client request verification, support for client self-pacing, and support for catch-up pacing reductions. A proxy server apparatus may also be used which employs both server-side and client-side pacing and may include caching and both cache and client preloading for minimized latency. A similar proxy server apparatus may be used to provide an efficient alternative to client polling for data from a polled data service, such as stock quotes etc., using streaming updates. The method may include support for stream modification through persistent client requests. | 08-04-2011 |
20120002717 | METHOD AND SYSTEM FOR LIVE STREAMING VIDEO WITH DYNAMIC RATE ADAPTATION - A live streaming system/method provides cross platform live streaming capabilities to mobile devices. A file format compatible with legacy HTTP infrastructure is used to deliver media over a persistent connection. Legacy client media players can dynamically change the encoded rate of the media delivered over a persistent connection. Standard HTTP servers may be used without modification, leveraging standard media players embedded in mobile devices for seamless media delivery over wireless networks with high bandwidth fluctuations. | 01-05-2012 |
20120004960 | METHOD AND SYSTEM FOR EFFICIENT STREAMING VIDEO DYNAMIC RATE ADAPTATION - A streaming media system employs dynamic rate adaptation. The method includes a file format compatible with legacy HTTP infrastructure to deliver media over a persistent connection. The method further includes the ability for legacy client media players to dynamically change the encoded delivery rate of the media over a persistent connection. The method provided works transparently with standard HTTP servers, requiring no modification and leverages standard media players embedded in mobile devices for seamless media delivery over wireless networks with high bandwidth fluctuations. A system is also specified for implementing a client and server in accordance with the method. | 01-05-2012 |
20120005364 | SYSTEM AND METHOD FOR NETWORK AWARE ADAPTIVE STREAMING FOR NOMADIC ENDPOINTS - In a system for streaming data over a network, the type and rate of streaming are automatically varied based on available network bandwidth. Video media is transcoded into different bit rate encodings that are divided into segment files. Segments are sent from a network-aware adaptive streaming (NAAS) server and reassembled and presented to a media player at a client device. The system may download additional segment files ahead of time from multiple NAAS servers to increase throughput. A playback status (“bookmark”) may be maintained to keep track of what the user has viewed and to allow the user to continue playing from where the user left off. The user may continue watching from the bookmark point on the same device or on a different device. | 01-05-2012 |
20120005365 | METHOD AND SYSTEM FOR EFFICIENT STREAMING VIDEO DYNAMIC RATE ADAPTATION - A streaming media system employs dynamic rate adaptation. The method includes a file format compatible with legacy HTTP infrastructure to deliver media over a persistent connection. The method further includes the ability for legacy client media players to dynamically change the encoded delivery rate of the media over a persistent connection. The method provided works transparently with standard HTTP servers, requiring no modification and leverages standard media players embedded in mobile devices for seamless media delivery over wireless networks with high bandwidth fluctuations. A system is also specified for implementing a client and server in accordance with the method. | 01-05-2012 |
20120005366 | METHOD AND APPARATUS FOR RETRIEVING AND RENDERING LIVE STREAMING DATA - A live streaming system/method provides cross platform live streaming capabilities to mobile devices. A file format compatible with legacy HTTP infrastructure is used to deliver media over a persistent connection. Legacy client media players can dynamically change the encoded rate of the media delivered over a persistent connection. Standard HTTP servers may be used without modification, leveraging standard media players embedded in mobile devices for seamless media delivery over wireless networks with high bandwidth fluctuations. | 01-05-2012 |
20120011267 | LIVE STREAMING MEDIA DELIVERY FOR MOBILE AUDIENCES - A live streaming system/method provides cross platform live streaming capabilities to mobile devices. The live streaming system includes a live streaming recorder operative to (1) capture a live media stream generated by a live media source and save the captured live media stream as a recorded stream in a recorded media file, and (2) transcode the recorded stream into a plurality of transcoded media files of respective different media encoding formats. The system further includes a stream distribution subsystem operative to generate a plurality of distributed media streams each generated from one or more of the transcoded media files, each distributed media stream being delivered to a corresponding set of the mobile endpoint devices. | 01-12-2012 |
20120265892 | METHOD AND SYSTEM FOR SECURE AND RELIABLE VIDEO STREAMING WITH RATE ADAPTATION - A system for media delivery includes a server-side proxy for aggregating and encrypting stream data for efficient HTTP-based distribution over an unsecured network. A client-side proxy decrypts and distributes the encapsulated stream data to client devices. A multicast-based infrastructure may be used for increased scalability. The encoded rate of the media delivered over the persistent HTTP proxy connections may be dynamically adapted. The client-side proxy may be integrated within a mobile device for maximum network security and reliability. | 10-18-2012 |
Patent application number | Description | Published |
20100173361 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 07-08-2010 |
20100173362 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 07-08-2010 |
20110229462 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 09-22-2011 |
20110236377 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 09-29-2011 |
20120231478 | TIVOZANIB RESPONSE PREDICTION - A diagnostic method for predicting whether a human tumor will be sensitive or resistant to treatment with tivozanib (AV-951) is disclosed. The method is based on measurement of macrophage content in a tissue sample from a tumor. Measurement of macrophage content can be based on analysis of macrophage marker gene expression, e.g., by RNA analysis or immunohistochemistry. | 09-13-2012 |
20120252829 | TIVOZANIB AND CAPECITABINE COMBINATION THERAPY - A method of treating a tumor in a subject using a combination of tivozanib and capecitabine is disclosed. | 10-04-2012 |
20130203963 | HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 08-08-2013 |
20130203970 | HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 08-08-2013 |
20140045715 | TIVOZANIB RESPONSE PREDICTION - A diagnostic method for predicting whether a human tumor will be sensitive or resistant to treatment with tivozanib (AV-951) is disclosed. The method is based on measurement of macrophage content in a tissue sample from a tumor. Measurement of macrophage content can be based on analysis of macrophage marker gene expression, e.g., by RNA analysis or immunohistochemistry. | 02-13-2014 |
20140178934 | HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 06-26-2014 |
20140178935 | HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 06-26-2014 |
Patent application number | Description | Published |
20090270527 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME - Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH—) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation. | 10-29-2009 |
20110068002 | ION EXCHANGE MEMBRANES - Highly energy efficient electrodialysis membranes having low operating costs and a novel process for their manufacture are described herein. The membranes are useful in the desalination of water and purification of waste water. They are effective in desalination of seawater due to their low electrical resistance and high permselectivity. These membranes are made by a novel process which results in membranes significantly thinner than prior art commercial electrodialysis membranes. The membranes are produced by polymerizing one or more monofunctional ionogenic monomers with at least one multifunctional monomer in the pores of a porous substrate. | 03-24-2011 |
20110097420 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME - Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component comprising a polymerizable resin comprising ethylenic unsaturated double bond, a second component comprising a compound comprising more than one type of amine selected from the group consisting of primary amines, secondary amines, tertiary amines and quaternary amines, and, optionally, the cement product includes a bioactive component to promote bone formation. | 04-28-2011 |
20130313118 | ANION EXCHANGE MEMBRANES AND PROCESS FOR MAKING - Embodiments of the present invention provide for anion exchange membranes and processes for their manufacture. The anion exchange membranes described herein are made the polymerization product of at least one functional monomer comprising a tertiary amine which is reacted with a quaternizing agent in the polymerization process. | 11-28-2013 |
20130317128 | Process for Making a Monomer Solution for Making Cation Exchange Membranes - A method of making a monomer solution of styrene sulfonic acid or the pyridine salt of styrene sulfonic acid or mixtures of both in an organic solvent, said solution being suitable for producing cation exchange membranes. The method comprises the steps of dissolving a metal salt of styrene sulfonate in said organic solvent and pyridinium styrene sulfonate. The mixture solution is reacted under conditions that generate a salt byproduct precipitate and the reactant product solution is collected. Embodiments of the present invention provide for cation exchange membranes and processes for their manufacture. Membranes made by the processes described herein combine low resistance and high permselectivity which make them highly effective for membrane components in desalination of water by electrodialysis (ED), as a power generating sources in reverse electrodialysis and as separators in fuels cells. | 11-28-2013 |
20140166488 | ION EXCHANGE MEMBRANES - Highly energy efficient electrodialysis membranes having low operating costs and a novel process for their manufacture are described herein. The membranes are useful in the desalination of water and purification of waste water. They are effective in desalination of seawater due to their low electrical resistance and high permselectivity. These membranes are made by a novel process which results in membranes significantly thinner than prior art commercial electrodialysis membranes. The membranes are produced by polymerizing one or more monofunctional ionogenic monomers with at least one multifunctional monomer in the pores of a porous substrate. | 06-19-2014 |
20140357754 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME - Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH—) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation. | 12-04-2014 |
Patent application number | Description | Published |
20080280168 | Fuel Cell - A fuel cell includes a membrane electrode assembly (MEA), a fuel delivery system distributing fuel to an anode side of the MEA, and a flow distributor delivering an oxidizer to a cathode side of the MEA. The flow distributor includes at least one serpentine channel through which the oxidizer is delivered to the cathode side of the MEA. Each portion of the serpentine channel delivers oxidizer to a portion of the cathode side of the MEA in contact, directly or through a porous diffuser, with the channel portion. The channel portion transfers water with the portion of the MEA in contact with the channel portion and also transfers water between adjacent channel portions via a water-permeable, gas impermeable material that defines at least a portion of the channel. | 11-13-2008 |
20130034258 | Surface Treatment for Ear Tips - An ear tip includes a body shaped to fit at least partially into the outer ear of a wearer and having a coefficient of friction greater than 2.0. The body has an outer surface having a permanent coating on at least the part shaped to fit into the outer ear with a coefficient of friction of less than 2.0. | 02-07-2013 |
20140064540 | Loudspeaker System - A loudspeaker system with an enclosure, an electro-acoustic transducer mounted in the enclosure so as to leave space inside of the enclosure that is unoccupied by the transducer, and an air-adsorbing material in the space inside of the enclosure that is unoccupied by the transducer. The air-adsorbing material includes a silicon-based zeolite with a small amount of a second metal. The mole ratio of silicon to the second metal is at least about 200 and is less than 400. | 03-06-2014 |
20140311820 | Three-Dimensional Air-Adsorbing Structure - A three-dimensional air-adsorbing structure for use in a volume in which there is a time-varying acoustic field. The structure has a three-dimensional, unitary, skeletal, porous scaffold having scaffold openings distributed within its volume, where the scaffold openings make up at least about 50% of the volume of the scaffold, air-adsorbing material particles, and a hydrophobic binder that couples air-adsorbing material particles to each other to form agglomerates and couples particles and agglomerates to the scaffold. The structure has structure openings in the agglomerates and structure openings between agglomerates, such structure openings being open to the outside environment, wherein the cumulative volume of the structure openings that have an apparent diameter larger than about 0.01 microns as measured by mercury porosimetry is at least about 40% of the volume of the air-adsorbing structure, and the cumulative volume of the structure openings that have an apparent diameter larger than about 5 microns as measured by mercury porosimetry is at least about 15% of the volume of the air-adsorbing structure. | 10-23-2014 |
20150068402 | Three-Dimensional Air-Adsorbing Structure - A three-dimensional air-adsorbing structure. The structure has a three-dimensional, unitary, skeletal, porous scaffold, air-adsorbing material particles, and one or more hydrophobic binders that couple air-adsorbing material particles to each other to form agglomerates and couples particles and agglomerates to the scaffold. The structure has structure openings in the agglomerates and structure openings between agglomerates, such structure openings being open to the outside environment. The air-adsorbing material and the agglomerates are coupled to the scaffold by creating a water-based emulsion of air-adsorbing material, agglomerates of the material, and binder, and then impregnating the scaffold with this emulsion. The emulsion is dried at least in part at a temperature below the freezing point of the emulsion. | 03-12-2015 |
Patent application number | Description | Published |
20080247955 | Inflammation treatment, detection and monitoring via TREM-1 - The present invention provides methods of treating inflammatory diseases/disorders in a subject by inhibiting/antagonizing TREM-1 expression/activity/signal transduction and/or DAP12/TyroBP expression and/or activity. Methods of detecting the presence of inflammatory disease in a subject by detecting TREM-1 and/or DAP12/TyroBP expression and/or activity in the subject or a sample obtained therefrom, wherein increased expression or activity is indicative of the inflammatory disease are also included. The present invention further provides methods for assessing the efficacy of a TREM-1-modulating agent administered to a patient by detecting levels of secreted phosphoprotein 1 (SPP1) and/or one or more other biomarkers in the patient or in a sample from the patient. | 10-09-2008 |
20080248460 | Composition and method for modulating an inflammatory response - The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LTβR) modulators, which activate or inhibit LTβR signaling. LTβR modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LTβR complex proteins that act as LTβR activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LTβR, its ligands, LIGHT and LTβ1α2, or its intracellular binding partners, that function to regulate LTβR signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LTβR signaling is provided. | 10-09-2008 |
20090092613 | Novel TNF receptor death domain ligand proteins and inhibitors of ligand binding - Novel TNF receptor death domain (“TNF-R1-DD”) ligand proteins are disclosed. Polynucleotides encoding the TNF-R1-DD ligand protein are also disclosed, along with vectors, host cells, and methods of making the TNF-R1-DD ligand protein. Pharmaceutical compositions containing the TNF-R1-DD ligand protein, methods of treating inflammatory conditions, and methods of inhibiting TNF-R death domain binding are also disclosed. Methods of identifying inhibitors of TNF-R death domain binding and inhibitors identified by such methods are also disclosed. | 04-09-2009 |
20090175874 | NOVEL INTERLEUKIN-1 RECEPTOR INTRACELLULAR LIGAND PROTEINS AND INHIBITORS OF LIGAND BINDING - Novel IL-1-R intracellular ligand proteins are disclosed. Polynucleotides encoding the IL-1-R intracellular ligand protein are also disclosed, along with vectors, host cells, and methods of making the IL-1-R intracellular ligand protein. Pharmaceutical compositions containing the IL-1-R intracellular ligand protein, methods of treating inflammatory conditions, and methods of inhibiting IL-1-R intracellular domain binding are also disclosed. Methods of identifying inhibitors of IL-1-R intracellular domain binding and inhibitors identified by such methods are also disclosed. | 07-09-2009 |
20100297147 | COMPOSITIONS AND METHODS FOR MODULATING TLR14 ACTIVITY - Methods and compositions for modulating neural cell function using antagonists of TLR14 are disclosed. In particular, methods for treating, preventing and/or diagnosing TLR14-associated neurodegenerative conditions and/or disorders are disclosed. Screening methods for evaluating TLR14 modulators, e.g., agonists and antagonists, are also disclosed. | 11-25-2010 |
Patent application number | Description | Published |
20090165082 | DIRECTORY INFRASTRUCTURE FOR SOCIAL NETWORKING WEB APPLICATION SERVICES - A computer-implemented method of implementing information security. The method can include receiving a user input comprising a first user identifier and at least a second user identifier, determining whether the first user identifier corresponds to at least one of a plurality of existing user profiles, and determining whether the second user identifier corresponds to at least one of the plurality of existing user profiles. When it is determined that the first user identifier does not correspond to at least one of the plurality of existing user profiles, but that the second user identifier does correspond to at least one of the plurality of existing user profiles, the method can include selecting the user profile to which the second user identifier corresponds, automatically generating a unique user identifier, and associating the unique user identifier with the selected user profile. | 06-25-2009 |
20140280583 | MULTI-TENANCY SUPPORT FOR ENTERPRISE SOCIAL BUSINESS COMPUTING - Mechanisms are provided for enabling collaboration across tenants in a multi-tenant environment using single sign-on (SSO) authentication/authorization. Various examples provide for creating a user account and provisioning a subscription to a user (e.g., to enable single sign-on authentication/authorization). The user is allowed to access services (e.g., collaborative services) in a multi-tenant environment by utilizing a subscription authorization of the user without prompting the user to authenticate by logging-in again (that is, without prompting the user to log-in again after the user has already logged-in and been authenticated for a given session). Other examples provide for mapping webspaces through URL hosts where each organization (that is, tenant) has its own set of namespace(s). | 09-18-2014 |
20140280939 | MULTI-TENANCY SUPPORT FOR ENTERPRISE SOCIAL BUSINESS COMPUTING - Mechanisms are provided for enabling collaboration across tenants in a multi-tenant environment using single sign-on (SSO) authentication/authorization. Various examples provide for creating a user account and provisioning a subscription to a user (e.g., to enable single sign-on authentication/authorization). The user is allowed to access services (e.g., collaborative services) in a multi-tenant environment by utilizing a subscription authorization of the user without prompting the user to authenticate by logging-in again (that is, without prompting the user to log-in again after the user has already logged-in and been authenticated for a given session). Other examples provide for mapping webspaces through URL hosts where each organization (that is, tenant) has its own set of namespace(s). | 09-18-2014 |
Patent application number | Description | Published |
20080308660 | Crusher block assembly for particulate size reduction system - The invention provides a crusher block assembly for a particulate size reduction system including a crusher block having an inboard face configured and adapted to cooperate with a swing hammer in a crusher chamber of a particulate size reduction system to crush particulate, and an outboard face for receiving an adjustment mechanism. The crusher block assembly also includes an adjustment mechanism joined to the outboard face on the crusher block. The adjustment mechanism is configured and adapted to adjust the position of the crusher block along a direction between an inboard location and an outboard location within the crusher chamber. The invention also provides a method of adjusting clearance between a swing hammer and a crusher block in a particulate size reduction system. | 12-18-2008 |
20090008487 | Loading system for vertical material size reduction system - The invention provides a loading system for a vertical material size reduction system including a pressure frame configured and adapted to be attached to at least one roller wheel assembly of the vertical material size reduction system. The loading system also includes at least one hydraulic cylinder operably connected to the pressure frame. The hydraulic cylinder is configured and adapted to apply a force to the pressure frame to apply pressure through the at least one roller wheel assembly to a grinding table of the vertical material size reduction system. The invention also provides a kit and a method for retrofitting a vertical material size reduction system accordingly. | 01-08-2009 |
20090011913 | Tire for material treatment system - The invention provides a tire and a roll wheel assembly used to crush material in a pulverizer including a generally toroidal body having a crushing surface on the outer periphery thereof. The crushing surface is configured and adapted to contact and crush the material within the pulverizer. At least one beveled surface is defined on an inner periphery of the body. The beveled surface is configured and adapted to engage a wedge disposed on a roller wheel of a roll wheel assembly to hold the tire on the roller wheel. The invention also provides a method of securing a tire to a roller assembly in a pulverizer for crushing material. | 01-08-2009 |
20090308959 | CRUSHER BLOCK ASSEMBLY FOR PARTICULATE SIZE REDUCTION SYSTEM - The invention provides a crusher block assembly for a particulate size reduction system including a crusher block having an inboard face configured and adapted to cooperate with a swing hammer in a crusher chamber of a particulate size reduction system to crush particulate, and an outboard face for receiving an adjustment mechanism. The crusher block assembly also includes an adjustment mechanism joined to the outboard face on the crusher block. The adjustment mechanism is configured and adapted to adjust the position of the crusher block along a direction between an inboard location and an outboard location within the crusher chamber. The invention also provides a method of adjusting clearance between a swing hammer and a crusher block in a particulate size reduction system. | 12-17-2009 |
20120243969 | COAL FLOW DISTRIBUTION CONTROLLERS FOR COAL PULVERIZERS - A solid particle flow distribution controller includes an extension skirt configured to be mounted to a discharge skirt at a division between an upstream solid particle conveyance pipe and a plurality of downstream pipes. The extension skirt includes a plurality of circumferential segments. Each segment is movably mounted to the discharge skirt for movement in an upstream and downstream direction with respect to the discharge skirt. The segments of the extension skirt are configured and adapted for motion in the upstream and downstream direction independent of one another to extend upstream of the discharge skirt as needed to improve solid particle distribution among the downstream pipes. | 09-27-2012 |
20150059140 | COAL FLOW DISTRIBUTION CONTROLLERS FOR COAL PULVERIZERS - A solid particle flow distribution controller includes an extension skirt configured to be mounted to a discharge skirt at a division between an upstream solid particle conveyance pipe and a plurality of downstream pipes. The extension skirt includes a plurality of circumferential segments. Each segment is movably mounted to the discharge skirt for movement in an upstream and downstream direction with respect to the discharge skirt. The segments of the extension skirt are configured and adapted for motion in the upstream and downstream direction independent of one another to extend upstream of the discharge skirt as needed to improve solid particle distribution among the downstream pipes. | 03-05-2015 |
Patent application number | Description | Published |
20090094450 | FIRMWARE IMAGE UPDATE AND MANAGEMENT - An embodiment of the present invention allows the firmware of one processor in a multi-processor system to be updated even if that processor is unstable due to a corruption of system software. For example, in a system that includes a primary processor and one or more secondary processors, an embodiment of the present invention allows the firmware of a secondary processor to be updated even if that processor is unstable due to a corruption of system software. An embodiment of the present invention also enables a network-based firmware update of a processor or microcontroller in a system, such as a consumer electronics device, wherein the processor or microcontroller requires such updates to occur via a serial port. | 04-09-2009 |
20110096789 | Isolating network traffic in multi-tenant virtualization enviroments - Managing data in a server system includes providing a plurality of servers, each having an internal gateway/switch that is accessible from outside the server, providing a plurality of virtual servers on at least some of the servers, where each of the virtual servers is accessible by the internal gateway/switch of the corresponding server, and accessing the data using the internal gateway/switch, where the internal gateway/switch determines which particular one of the virtual servers contain the data and then accesses the particular virtual server to provide the data. Managing data in a server system may also include associating portions of the data to tenants of the server system. Each of the servers may maintain a table that correlates tenants with the virtual servers maintained thereby and the internal gateway/switch may use the table to determine which particular one of the virtual servers contains data for a particular tenant. | 04-28-2011 |
20110261834 | LEGACY DEVICE BRIDGE FOR RESIDENTIAL OR NON-RESIDENTIAL NETWORKS - A legacy device bridge for use in a network, such as a wired or wireless residential network, is provided. The legacy device bridge performs protocol conversion to enable a network-attached entity that uses a packet-based communication protocol to communicate with and control legacy devices, such as consumer electronics, that rely exclusively on infrared (IR) or serial communication protocols. The legacy device bridge also performs a virtualization function that allows legacy devices to be advertised to the network as devices that comply with a packet-based discovery and control protocol, and to be controlled as such. The legacy device bridge is also adapted to probe, deduce and publish information relating to the state of a legacy device to other entities on the network. | 10-27-2011 |
20110283274 | FIRMWARE IMAGE UPDATE AND MANAGEMENT - An embodiment of the present invention allows the firmware of one processor in a multi-processor system to be updated even if that processor is unstable due to a corruption of system software. For example, in a system that includes a primary processor and one or more secondary processors, an embodiment of the present invention allows the firmware of a secondary processor to be updated even if that processor is unstable due to a corruption of system software. An embodiment of the present invention also enables a network-based firmware update of a processor or microcontroller in a system, such as a consumer electronics device, wherein the processor or microcontroller requires such updates to occur via a serial port. | 11-17-2011 |
Patent application number | Description | Published |
20090007064 | Size vector sharing in code generated for variable-sized signals - A method and apparatus to generate code to represent a graphical model formed of multiple graphical modeling components and at least one variable-sized signal is presented. Each variable-sized signal is represented using a size-vector in the generated code. The generated code is optimized by representing multiple variable-sized signals with the same size-vector such that at least two variable-sized signals share a size-vector in the generated code. The size of the variable-sized signal is capable of changing during the execution of the graphical model. The method and apparatus also identifies the owners of the variable-sized signals. | 01-01-2009 |
20110239202 | APPLICATION OF OPTIMIZATION TECHNIQUES TO INTERMEDIATE REPRESENTATIONS FOR CODE GENERATION - The present invention provides a method and system for optimization of an intermediate representation in a graphical modeling environment. A first intermediate representation is provided. At least one optimization technique is applied to the first intermediate representation. A second intermediate representation is generated responsive to the application of the at least one optimization technique to the first intermediate representation. | 09-29-2011 |
20120005650 | HARDWARE SPECIFIC CODE GENERATION - A computer-implemented method for generating code based on a graphical model may include: translating the graphical model into a graphical model code, the graphical model code including a first graphical model code function; performing a lookup of the first graphical model code function in a hardware specific library, the hardware specific library comprising a plurality of relationships between graphical model code functions and hardware specific functions, where the first graphical model code function is one of the graphical model code functions; obtaining a matched hardware specific function based on the lookup, wherein the matched hardware specific function is one of the hardware specific functions from the hardware specific library; and modifying the graphical model code based on the matched hardware specific function. | 01-05-2012 |
20120096430 | TRACEABILITY IN A MODELING ENVIRONMENT - Exemplary embodiments employ a mapping among entities that are related to each other. The entities may include a graphical model, generated code, a generated report, a requirements document and/or an intermediate representation. The mapping may facilitate graphical identifications between parts of one entity that maps to part of another entity. The graphical identification may occur based on a selection of a part in one of the entities. | 04-19-2012 |
20120096439 | TRACEABILITY IN A MODELING ENVIRONMENT - Exemplary embodiments employ a mapping among entities that are related to each other. The entities may include a graphical model, generated code, a generated report, a requirements document and/or an intermediate representation. The mapping may facilitate graphical identifications between parts of one entity that maps to part of another entity. The graphical identification may occur based on a selection of a part in one of the entities. | 04-19-2012 |
20120124552 | TRACEABILITY IN A MODELING ENVIRONMENT - Exemplary embodiments employ a mapping among entities that are related to each other. The entities may include a graphical model, generated code, a generated report, a requirements document and/or an intermediate representation. The mapping may facilitate graphical identifications between parts of one entity that maps to part of another entity. The graphical identification may occur based on a selection of a part in one of the entities. | 05-17-2012 |
Patent application number | Description | Published |
20120254827 | VERIFICATION OF COMPUTER-EXECUTABLE CODE GENERATED FROM A MODEL - In an embodiment, a model is sliced into a plurality of slices. A slice in the plurality of slices is selected. A portion of code, that corresponds to the selected slice, is identified from code generated from the model. The identified code is verified to be equivalent to the selected slice. Equivalence may include equivalent functionality, equivalent data types, equivalent performance, and/or other forms of equivalence between the selected slice and the identified generated code. | 10-04-2012 |
20120254830 | VERIFICATION OF COMPUTER-EXECUTABLE CODE GENERATED FROM A MODEL - In an embodiment, a model is sliced into a plurality of slices. A slice in the plurality of slices is selected. A portion of code, that corresponds to the selected slice, is identified from code generated from the model. The identified code is verified to be equivalent to the selected slice. Equivalence may include equivalent functionality, equivalent data types, equivalent performance, and/or other forms of equivalence between the selected slice and the identified generated code. | 10-04-2012 |
20130263082 | APPLICATION OF OPTIMIZATION TECHNIQUES TO INTERMEDIATE REPRESENTATIONS FOR CODE GENERATION - The present invention provides a method and system for optimization of an intermediate representation in a graphical modeling environment. A first intermediate representation is provided. At least one optimization technique is applied to the first intermediate representation. A second intermediate representation is generated responsive to the application of the at least one optimization technique to the first intermediate representation. | 10-03-2013 |
20140380269 | VERIFICATION OF COMPUTER-EXECUTABLE CODE GENERATED FROM A MODEL - In an embodiment, a model is sliced into a plurality of slices. A slice in the plurality of slices is selected. A portion of code, that corresponds to the selected slice, is identified from code generated from the model. The identified code is verified to be equivalent to the selected slice. Equivalence may include equivalent functionality, equivalent data types, equivalent performance, and/or other forms of equivalence between the selected slice and the identified generated code. | 12-25-2014 |
Patent application number | Description | Published |
20110163062 | SELF-ALIGNED BARRIER AND CAPPING LAYERS FOR INTERCONNECTS - An interconnect structure for integrated circuits for copper wires in integrated circuits and methods for making the same are provided. Mn, Cr, or V containing layer forms a barrier against copper diffusing out of the wires, thereby protecting the insulator from premature breakdown, and protecting transistors from degradation by copper. The Mn, Cr, or V containing layer also promotes strong adhesion between copper and insulators, thus preserving the mechanical integrity of the devices during manufacture and use, as well as protecting against failure by electromigration of the copper during use of the devices and protecting the copper from corrosion by oxygen or water from its surroundings. In forming such integrated circuits, certain embodiments of the invention provide methods to selectively deposit Mn, Cr, V, or Co on the copper surfaces while reducing or even preventing deposition of Mn, Cr, V, or Co on insulator surfaces. Catalytic deposition of copper using a Mn, Cr, or V containing precursor and an iodine or bromine containing precursor is also provided. | 07-07-2011 |
20140045331 | SELF-ALIGNED BARRIER AND CAPPING LAYERS FOR INTERCONNECTS - An interconnect structure for integrated circuits for copper wires in integrated circuits and methods for making the same are provided. Mn, Cr, or V containing layer forms a barrier against copper diffusing out of the wires, thereby protecting the insulator from premature breakdown, and protecting transistors from degradation by copper. The Mn, Cr, or V containing layer also promotes strong adhesion between copper and insulators, thus preserving the mechanical integrity of the devices during manufacture and use, as well as protecting against failure by electromigration of the copper during use of the devices and protecting the copper from corrosion by oxygen or water from its surroundings. In forming such integrated circuits, certain embodiments of the invention provide methods to selectively deposit Mn, Cr, V, or Co on the copper surfaces while reducing or even preventing deposition of Mn, Cr, V, or Co on insulator surfaces. Catalytic deposition of copper using a Mn, Cr, or V containing precursor and an iodine or bromine containing precursor is also provided. | 02-13-2014 |